{"id":23503,"date":"2023-06-16T12:12:32","date_gmt":"2023-06-16T16:12:32","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/corvus-pharmaceuticals-shares-drop-26-on-cpi-818-immunotherapy-trial-data\/"},"modified":"2023-06-16T12:12:33","modified_gmt":"2023-06-16T16:12:33","slug":"corvus-pharmaceuticals-shares-drop-26-on-cpi-818-immunotherapy-trial-data","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=23503","title":{"rendered":"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data"},"content":{"rendered":"<div id=\"js-article__body\" itemprop=\"articleBody\" data-sbid=\"MW-BT-CO-20230615-707390\" role=\"document\">\n<p>By Ada Hui<\/p>\n<pre><\/pre>\n<p>Corvus Pharmaceuticals shares fell 26%, to $2.49, on Thursday after the clinical-stage biopharmaceutical company reported new interim data from its Phase 1\/1b clinical trial of CPI-818, an ITK inhibitor it is developing to treat solid and hematological cancers.<\/p>\n<div class=\"paywall\">\n<p>The interim trial data taken as of mid-May showed that out of 30 patients with relapsed T-cell lymphoma who were dosed with 200 mg of CPI-818 twice a day, only three patients experienced complete responses and three patients experienced partial responses.<\/p>\n<p>One partial response saw continued tumor regression. One complete response and the other two partial responses remained on therapy.<\/p>\n<p>According to the company, CPI-818 increases tumor-killing T cells by modulating T cell differentiation and reducing T cell exhaustion.<\/p>\n<p>Corvus also said it is testing CPI-818 in B cell lymphoma and colon cancer models and that it is planning to meet with the U.S. Food and Drug Administration in the third quarter to discuss potentially registering a Phase 3 clinical trial to evaluate CPI-818 for the treatment of T-cell lymphoma.<\/p>\n<pre><\/pre>\n<p>Write to Ada Hui at ada.hui@wsj.com<\/p>\n<pre><\/pre>\n<\/p><\/div>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.marketwatch.com\/story\/corvus-pharmaceuticals-shares-drop-26-on-cpi-818-immunotherapy-trial-data-eb882541?mod=investing\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By Ada Hui Corvus Pharmaceuticals shares fell 26%, to $2.49, on Thursday after the clinical-stage biopharmaceutical company reported new interim data from its Phase 1\/1b clinical trial of CPI-818, an ITK inhibitor it is developing to treat solid and hematological cancers. The interim trial data taken as of mid-May showed that out of 30 patients [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1898,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-23503","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data | iFintechWorld<\/title>\n<meta name=\"description\" content=\"By Ada Hui Corvus Pharmaceuticals shares fell 26%, to $2.49, on Thursday after the clinical-stage biopharmaceutical company reported new interim data from\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=23503\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"By Ada Hui Corvus Pharmaceuticals shares fell 26%, to $2.49, on Thursday after the clinical-stage biopharmaceutical company reported new interim data from\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=23503\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-16T16:12:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-16T16:12:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=23503#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=23503\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data\",\"datePublished\":\"2023-06-16T16:12:32+00:00\",\"dateModified\":\"2023-06-16T16:12:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=23503\"},\"wordCount\":190,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=23503#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=23503\",\"url\":\"https:\/\/ifintechworld.com\/?p=23503\",\"name\":\"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-06-16T16:12:32+00:00\",\"dateModified\":\"2023-06-16T16:12:33+00:00\",\"description\":\"By Ada Hui Corvus Pharmaceuticals shares fell 26%, to $2.49, on Thursday after the clinical-stage biopharmaceutical company reported new interim data from\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=23503#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=23503\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=23503#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data | iFintechWorld","description":"By Ada Hui Corvus Pharmaceuticals shares fell 26%, to $2.49, on Thursday after the clinical-stage biopharmaceutical company reported new interim data from","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=23503","og_locale":"en_US","og_type":"article","og_title":"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data | iFintechWorld","og_description":"By Ada Hui Corvus Pharmaceuticals shares fell 26%, to $2.49, on Thursday after the clinical-stage biopharmaceutical company reported new interim data from","og_url":"https:\/\/ifintechworld.com\/?p=23503","og_site_name":"iFintechWorld","article_published_time":"2023-06-16T16:12:32+00:00","article_modified_time":"2023-06-16T16:12:33+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=23503#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=23503"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data","datePublished":"2023-06-16T16:12:32+00:00","dateModified":"2023-06-16T16:12:33+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=23503"},"wordCount":190,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=23503#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=23503","url":"https:\/\/ifintechworld.com\/?p=23503","name":"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-06-16T16:12:32+00:00","dateModified":"2023-06-16T16:12:33+00:00","description":"By Ada Hui Corvus Pharmaceuticals shares fell 26%, to $2.49, on Thursday after the clinical-stage biopharmaceutical company reported new interim data from","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=23503#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=23503"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=23503#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Corvus Pharmaceuticals Shares Drop 26% on CPI-818 Immunotherapy Trial Data"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/23503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23503"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/23503\/revisions"}],"predecessor-version":[{"id":23504,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/23503\/revisions\/23504"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/1898"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}